Here, we identify endogenous T cell responses in patients with cancer to 3 different recurrent oncogenic driver mutations: BRAF V600E, KRAS G12V and the ERBB2 (Her2) internal tandem duplication (Her2-ITD). This evidence concerns the gene KRAS and cancer.